Zenas BioPharma (ZBIO) Retained Earnings (2023 - 2026)

Zenas BioPharma's Retained Earnings history runs 4 years deep, the most recent figure standing at -$846.1 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 219.99% year-over-year to -$846.1 million in Q1 2026; TTM through Mar 2026 was -$846.1 million, a 219.99% decrease from a year earlier, with the FY2025 full-year figure at -$64000.0, down 132.99% from the prior year.
• Retained Earnings declined to -$846.1 million in Q1 2026 per ZBIO's latest filing, from -$64000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $705.1 million in Q1 2025 and bottomed at -$846.1 million in Q1 2026.
• The 4-year median for Retained Earnings is -$79000.0 (2025), against an average of -$125.0 million.
• Across the five-year window, Retained Earnings soared 424.32% in 2024 and plunged 219.99% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $37000.0 in 2023, then surged by 424.32% to $194000.0 in 2024, then slumped by 132.99% to -$64000.0 in 2025, then tumbled by 1321954.69% to -$846.1 million in 2026.
• Per Business Quant, the three latest ZBIO Retained Earnings figures stand at -$846.1 million (Q1 2026), -$64000.0 (Q4 2025), and -$524.7 million (Q3 2025).